RNA replicons provide the genetic instructions to the body’s own cells to produce ample amounts of protein and unleash an immune response. Replicons carry the RNA code for a self-replication engine as well as multiple antigens that signal for immune response. RNA replicons can trigger antigen expression within host cells, increase T-cell response (including when the host is already infected), and lower dose requirements compared to traditional RNA-based vaccine and therapeutic approaches.
January 7, 2018
Arcturus Therapeutics to Present in a Panel Discussion at East/West CEO Conference Called “Challenges and Opportunities in Biotech” on Sunday, Jan 7th 2018, from 11:20 am - 11:50 am.
January 5, 2018
Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics